Quantitative Proteomic and Phosphoproteomic Profiling of Lung Tissues from Pulmonary Arterial Hypertension Rat Model
暂无分享,去创建一个
Haiyang Tang | Meijuan Ren | Ang Luo | Yan-Fang Jia | Chenxin Gu | Xia Zhou | Rongrong Hao | Yafang Yu | Chenxin Gu
[1] W. Xie,et al. Inhibition of Bruton's Tyrosine Kinase Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Modulating Macrophage Polarization , 2022, Oxidative medicine and cellular longevity.
[2] M. Humbert,et al. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension , 2021, International journal of molecular sciences.
[3] Lingfei Li,et al. Microtubule associated protein 4 (MAP4) phosphorylation reduces cardiac microvascular density through NLRP3-related pyroptosis , 2021, Cell death discovery.
[4] Dana R. Valley,et al. A proteogenomic portrait of lung squamous cell carcinoma , 2021, Cell.
[5] Xiaochen Bo,et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.
[6] Yuan Zhang,et al. Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models , 2021, Frontiers in Pharmacology.
[7] J. Leopold,et al. Integrative Omics to Characterize and Classify Pulmonary Vascular Disease. , 2021, Clinics in chest medicine.
[8] Md Khadem Ali,et al. Novel Advances in Modifying BMPR2 Signaling in PAH , 2020, Genes.
[9] Liang-di Xie,et al. Transcriptomic analysis identifies Toll‐like and Nod‐like pathways and necroptosis in pulmonary arterial hypertension , 2020, Journal of cellular and molecular medicine.
[10] J. Elinoff,et al. How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. , 2020, Current opinion in pulmonary medicine.
[11] A. Malik,et al. Plasmalemmal Vesicle Associated Protein (PV1) in Caveolae Controls Lung Endothelial Permeability. , 2020, American journal of respiratory cell and molecular biology.
[12] Jeffrey R. Whiteaker,et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma , 2020, Cell.
[13] Hongmei Wu,et al. Protein expression profile changes of lung tissue in patients with pulmonary hypertension , 2020, PeerJ.
[14] F. Cheng,et al. Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension , 2019, Scientific Reports.
[15] R. Johns,et al. HIMF (Hypoxia-Induced Mitogenic Factor) Signaling Mediates the HMGB1 (High Mobility Group Box 1)-Dependent Endothelial and Smooth Muscle Cell Cross Talk in Pulmonary Hypertension. , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[16] Guo Ci Teo,et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.
[17] Li Zhang,et al. Revealing the pathogenic changes of PAH based on multiomics characteristics , 2019, Journal of Translational Medicine.
[18] Lingfei Li,et al. Phosphorylation of Microtubule- Associated Protein 4 Promotes Hypoxic Endothelial Cell Migration and Proliferation , 2019, Front. Pharmacol..
[19] Alireza Hadj Khodabakhshi,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[20] W. Chung,et al. Genetics and genomics of pulmonary arterial hypertension , 2019, European Respiratory Journal.
[21] Traci L. Marin,et al. AMP‐activated Protein Kinase Phosphorylation of Angiotensin‐Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension , 2018, American journal of respiratory and critical care medicine.
[22] M. Humbert,et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension , 2018, The Journal of clinical investigation.
[23] M. Nishimura,et al. Decreased haptoglobin levels inversely correlated with pulmonary artery pressure in patients with pulmonary arterial hypertension , 2017, Medicine.
[24] M. Humbert,et al. Epidemiology and treatment of pulmonary arterial hypertension , 2017, Nature Reviews Cardiology.
[25] N. Morrell,et al. HIF2α–arginase axis is essential for the development of pulmonary hypertension , 2016, Proceedings of the National Academy of Sciences.
[26] B. Dahal,et al. Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis , 2015, European Respiratory Journal.
[27] J. Garcia,et al. Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[28] M. Capecchi,et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension , 2014, Nature Medicine.
[29] Nadia Hedhli,et al. Cardiovascular effects of neuregulin-1/ErbB signaling: role in vascular signaling and angiogenesis. , 2014, Current pharmaceutical design.
[30] T. Henriques-Coelho,et al. Cellular interplay in pulmonary arterial hypertension: implications for new therapies. , 2014, Biochimica et biophysica acta.
[31] M. Humbert,et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer , 2013, European Respiratory Review.
[32] R. Dweik,et al. Causes and circumstances of death in pulmonary arterial hypertension. , 2013, American journal of respiratory and critical care medicine.
[33] J. Wharton,et al. Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension , 2010, Circulation.
[34] J. Siamwala,et al. eNOS phosphorylation in health and disease. , 2010, Biochimie.
[35] R. Stan,et al. PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. , 2004, Molecular biology of the cell.
[36] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[37] P. Shannon,et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks , 2003 .
[38] J. Ross,et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. Christ,et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. , 2001, The Journal of biological chemistry.
[40] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[41] G. Palade,et al. PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[42] OUP accepted manuscript , 2021, Nucleic Acids Research.
[43] Haiyang Tang,et al. Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension. , 2021, Advances in experimental medicine and biology.